Prostate cancers are either low-grade, low-risk forms that may be monitored but otherwise untreated, or they’re serious enough to require surgery and radiation. Monitoring can cause patients anxiety.

AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for prostate tissue ablation. The clearance for the NanoKnife System for prostate ...

Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation therapy for cancers of the prostate, kidneys and bladder. The series C round ...

The first prostate ablation treatment with the Ablatherm Robotic HIFU was performed at the Gramercy Surgery Center in New York. 1. Ivan Grunberger, MD, chief of urology at New York Methodist Hospital ...

Credit: Thinkstock By 5 years, 92% of men recovered pad-free continence, and 87% had preserved erectile function sufficient for penetration. MRI-guided whole-gland transurethral ultrasound ablation ...

An expert answered CURE® readers’ questions on several aspects of a prostate cancer journey, including treatment options and sexual function. A prostate cancer journey can involve plenty of questions.

— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading ...

Study results are based on Surveillance, Epidemiology, and End Results-Medicare data for 166,581 patients receiving surgery or radiation for localized prostate cancer.

Lake Street Life-Sciences Invitational: Profound is scheduled to participate in a series of one-on-one meetings February 4 th- 5 th in Scottsdale, AZ. BTIG 13th Annual MedTech, Digital Health, Life ...

TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

The global ablation technology market growth is driven by rising cardiovascular and cancer cases, and the increasing adoption ...

— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...